At a glance

PE-22-28 Quick Reference

Research focus: Mood & neural plasticity
A different target from conventional monoamine-based approaches
Primary target: TREK-1
A background potassium channel; also called KCNK2
Community routes: SubQ / nasal
Dose and frequency references vary considerably
Evidence: Preclinical
Human efficacy, dose-finding, and long-term safety are unestablished

Overview

What Is PE-22-28?

PE-22-28 is a synthetic seven-amino-acid fragment developed from spadin, a peptide derived from the sortilin propeptide. The name refers to residues 22–28 of that parent sequence. The 2017 PE-22-28 study identified it as a potent blocker of the TREK-1 potassium channel.

That gives it a different research rationale from peptides such as Selank and Semax. Interest centers on mood and the brain’s ability to adapt, rather than an immediate stimulant-like boost.

The original spadin research helped establish TREK-1 blockade as an antidepressant research strategy in mice. A later TREK-1 / spadin mouse study also examined depression-related behavior and hippocampal synaptic changes. Those findings concern a target and parent compound; they do not make PE-22-28 a proven human antidepressant.

Mechanism

PE-22-28 Mechanism of Action

TREK-1 Inhibition

The 2017 PE-22-28 study reported channel inhibition at an IC50 of about 0.12 nM in its cell assay. This is laboratory potency, not a human dose or proof of stronger clinical effects.

Background Electrical Activity

TREK-1 contributes to background potassium conductance. The original spadin research connected blocking this channel with changes in neuronal activity and depression-related behavior in mice.

Neural Plasticity

The TREK-1 / spadin mouse study linked TREK-1 inhibition with hippocampal synaptic markers and behavioral changes. This supports the target’s research interest without proving cognitive enhancement in people.

Molecule-Specific Evidence

Chemical modifications can change how a peptide behaves. Longer-lasting results reported for modified analogues should not be presented as the known half-life of an ordinary PE-22-28 vial.

Research interests

PE-22-28 Potential Benefits

These are reasons the compound attracts research and community interest. They are not established treatment outcomes.

Mood Research

The main interest is whether a distinct channel target can meaningfully affect mood. Human antidepressant efficacy has not been demonstrated.

Plasticity Research

Parent spadin and TREK-1 studies investigate the brain’s capacity to adapt. That is a research rationale, not a promise of new neurons or better memory.

A Different Mechanistic Angle

PE-22-28 is discussed when researchers want to compare channel signaling with other nootropic approaches. A different mechanism does not establish a better outcome.

Community Mood Reports

Some users describe a mild mood lift. Reports are inconsistent, often brief, and may involve several compounds at once.

Comparative Research

Comparing a single compound at a time makes subjective changes easier to attribute than immediately assembling a multi-peptide stack.

Tracking Over Time

Sleep, mood, motivation, and unwanted effects are more useful observations than assuming a particular feeling proves a biological mechanism.

Protocol planning

PE-22-28 Dosing Protocol

Members Access Only

Sign in or create a free account to view this content.

Preparation

PE-22-28 Reconstitution & Nasal Preparation

Reconstitution Example

10mg PE-22-28 + 2mL BAC water

Final concentration5mg/mL

Reconstitution steps

1

Prepare

Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.

2

Add 2mL BAC water

Use a new sterile syringe and needle to add 2mL bacteriostatic water slowly down the vial wall. Gently swirl to dissolve; avoid vigorous shaking.

3

Record the concentration

10mg ÷ 2mL = 5mg/mL. Use this concentration in the calculator for the intended amount; syringe marks measure volume, not the peptide dose.

4

Storage

Refrigerate after reconstitution and protect from light. Record the preparation date in your research journal. A compound-specific storage lifetime has not been established.

Nasal spray preparation example

10mg PE-22-28 in 5mL final volume

At 0.1mL per spray200mcg/spray

Nasal preparation

1

Prepare

Reported community preparation: equal parts sterile, preservative-free 0.9% saline and bacteriostatic 0.9% sodium chloride. The bacteriostatic component contains benzyl alcohol. This method has not established PE-22-28 nasal stability or preservative tolerability.

2

Measure the final mixture

The example contains 10mg PE-22-28 in 5mL final liquid volume: 2.5mL sterile 0.9% saline plus 2.5mL bacteriostatic 0.9% sodium chloride. This gives 2mg/mL.

3

Confirm pump output

At a measured 0.1mL per spray, 2mg/mL delivers 200mcg per spray. Check the bottle specification and actual output; another pump volume changes the amount per spray.

4

Storage

Keep refrigerated and protected from light according to the formulation instructions. Record the prep date in your research journal.

N=1 reports

PE-22-28 Community Experience

Self-reported anecdotal experiences aggregated from public & private peptide community discussions and anonymous peptideprotocols.app user reports. This information does not carry the same weight as published research.

Positive Reports

A public discussion includes a user describing a gentle mood lift during use.
Some discussions frame the appeal as a subtle change rather than a strong stimulant feeling.
Interest is often driven by the different mechanism rather than an established track record.

Negative & Mixed Reports

The same discussion describes the benefit as limited and temporary, with other compounds preferred.
Small, self-selected reports cannot tell us how often it works or how often unwanted effects occur.
Multiple compounds, changing sleep, and inconsistent product quality make causal claims difficult.

Stacking & synergy

PE-22-28 Stacking & Synergy

These are possible research-interest pairings, not demonstrated synergies or tested combination regimens.

PE-22-28 + Selank

The community rationale is mood plus calmer stress responses. Selank adds a different research background, but no controlled study establishes the combination’s benefit or interactions.

PE-22-28 + Semax

Semax is discussed around cognition and neurotrophic signaling. This is a theoretical mood-and-focus pairing; adding both at once makes individual effects harder to identify.

PE-22-28 + Pinealon

Pinealon brings a separate neural-resilience and sleep research interest. The pairing remains exploratory, with no validated combination protocol.

Safety notes

PE-22-28 Side Effects & Safety

The available evidence does not establish a reliable human side-effect frequency, interaction profile, or safe duration of use.

What to Monitor

Changes in sleep, anxiety, agitation, or mood deserve attention; their frequency with this compound is unknown.
SubQ products introduce injection-site and contamination risks. Nasal formulations can cause local irritation.

Important Unknowns

No adequate human evidence establishes long-term neurological or cardiovascular safety.
Absence of adverse-event reports in small community discussions does not demonstrate safety.

Precautions & Interactions

When to Avoid Self-Experimentation

Pregnancy, breastfeeding, and use in children lack safety evidence.
A history of mania, unstable psychiatric symptoms, or current suicidal thoughts calls for professional care rather than an experimental peptide.

Medication & Product Context

Interactions with antidepressants, mood stabilizers, stimulants, and other centrally active compounds have not been characterized. Review combinations with a qualified clinician.
Do not abruptly stop prescribed psychiatric treatment to substitute PE-22-28.
A COA can document an assay result; it does not establish clinical efficacy or prove a finished vial is sterile.

Final verdict

Peptide Protocols Verdict on PE-22-28

Not medical advice. This editorial is our own opinion piece based off the experience of our own lab rats.

Our take

PE-22-28 is interesting because it gives mood-focused research a different mechanism to explore. That is enough to earn a place in the library, but it is still a niche compound with a small practical evidence base. We would put more weight on careful, repeatable observations than on big promises about rapid antidepressant effects or lasting brain changes.

The appeal is the scientific direction; the limitation is how much remains unanswered in humans. Community dosing references disagree, and adding several nootropic peptides at once makes the result harder to judge. Our C reflects that balance: worth following, with too many open questions to call it a dependable first choice.